PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202333	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-8-oxooctanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-19-0	CRBN	BRD4	Inquiry
Molecular Weight: 957.15 Molecular Formula: C51H64N12O7 Density: 1.44±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202334	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(3-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-48-0	CRBN	BCR-ABL	Inquiry
Molecular Weight: 815.31 Molecular Formula: C38H39ClN10O7S Density: 1.497±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202335	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-49-1	CRBN	BCR-ABL	Inquiry
Molecular Weight: 859.37 Molecular Formula: C40H43ClN10O8S Density: 1.471±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202336	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-50-4	CRBN	BCR-ABL	Inquiry
Molecular Weight: 903.42 Molecular Formula: C42H47ClN10O9S Density: 1.449±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202337	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-51-5	CRBN	BCR-ABL	Inquiry
Molecular Weight: 947.47 Molecular Formula: C44H51ClN10O10S Density: 1.429±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202338	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-oyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-52-6	CRBN	BCR-ABL	Inquiry
Molecular Weight: 991.53 Molecular Formula: C46H55ClN10O11S Density: 1.412±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202339	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-55-9	CRBN	BCR-ABL	Inquiry
Molecular Weight: 785.29 Molecular Formula: C37H37ClN10O6S Density: 1.505±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202340	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-56-0	CRBN	BCR-ABL	Inquiry
Molecular Weight: 799.31 Molecular Formula: C38H39ClN10O6S Density: 1.485±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202341	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-58-2	CRBN	BCR-ABL	Inquiry
Molecular Weight: 827.37 Molecular Formula: C40H43ClN10O6S Density: 1.448±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202342	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)thio)acetyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2378581-07-6	CRBN	BCR-ABL	Inquiry
Molecular Weight: 774.29 Molecular Formula: C35H32ClN9O6S2 Density: 1.60±0.1 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202343	N-(2-Chloro-6-methylphenyl)-2-((6-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-53-7	CRBN	BCR-ABL	Inquiry
Molecular Weight: 757.23 Molecular Formula: C35H33ClN10O6S Density: 1.549±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202344	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-90-2	CRBN	BCR-ABL	Inquiry
Molecular Weight: 758.22 Molecular Formula: C35H32ClN9O7S Density: 1.537±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202345	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)propanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-89-9	CRBN	BCR-ABL	Inquiry
Molecular Weight: 756.25 Molecular Formula: C36H34ClN9O6S Density: 1.506±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202346	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)sulfonyl)acetyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2378581-19-0	CRBN	BCR-ABL	Inquiry
Molecular Weight: 806.28 Molecular Formula: C35H32ClN9O8S2 Density: 1.577±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202347	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)thio)ethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2378581-37-2	CRBN	BCR-ABL BCR-ABL E255V BCR-ABL F317L BCR-ABL F317V BCR-ABL G250E BCR-ABL T315A BCR-ABL V299L	Inquiry
Molecular Weight: 760.29 Molecular Formula: C35H34ClN9O5S2 Density: 1.56±0.1 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202348	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)acetyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2378581-12-3	CRBN	BCR-ABL	Inquiry
Molecular Weight: 760.29 Molecular Formula: C35H34ClN9O5S2 Density: 1.56±0.1 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202349	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)thio)ethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2378581-39-4	CRBN	BCR-ABL	Inquiry
Molecular Weight: 746.32 Molecular Formula: C35H36ClN9O4S2 Density: 1.52±0.1 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202350	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide		CRBN	BCR-ABL	Inquiry
Molecular Weight: 771.29 Molecular Formula: C37H39ClN10O5S Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202351	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-5-oxopentyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide		CRBN	BCR-ABL	Inquiry
Molecular Weight: 799.31 Molecular Formula: C38H39ClN10O6S Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.
	BPL-202352	N-(2-Chloro-6-methylphenyl)-2-((6-(4-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)pentanoyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide	2376047-84-4	CRBN	BCR-ABL	Inquiry
Molecular Weight: 785.33 Molecular Formula: C38H41ClN10O5S Density: 1.449±0.06 g/cm3 Description: It is a BCR-ABL PROTAC synthesized by conjugating BCR-ABL inhibitor dasatinib to the CRBN ligand including pomalidomide and lenalidomide.